Amid recent controversy about the skyrocketing price of EpiPens—potentially life-saving medical devices designed to stop a severe allergic reaction—the manufacturer has taken steps to reduce costs for health care consumers. First, on August 25, 2016, in a move many considered "too little," Mylan announced it would lower out-of-pocket expenses and co-payments for certain insured patients, based on income and insurance, and would increase the number of uninsured patients eligible for free EpiPens.
On August 29, the company announced the launch of a generic version, which will be available for about half the price. The new device will be identical to the EpiPen in formula and function, according to Mylan.
Another epinephrine injector—Adrenaclick—as well as a generic version, is currently available in the U.S., but supplies are limited and the manufacturer is not able to produce it in large enough quantities. Additional options may also be on the horizon, but an FDA ruling delayed marketing of a competitor's auto-injection device until at least 2017.